Tyra Biosciences, Inc. Stock Split Ratio
Tyra Biosciences, Inc. (TYRA) had Stock Split Ratio of 2.60% as of 2021-09-17, per its 10-Q filed 2021-11-03.
Discontinued › Notes › Equity
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2022-11-03
- 2021-09-17: Stockholders' Equity Note, Stock Split, Conversion Ratio 2.60%.
- 2021-09-07: Stockholders' Equity Note, Stock Split, Conversion Ratio 0.00%; Stockholders' Equity Note, Stock Split, Conversion Ratio as first filed 2.60%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio as first filed |
|---|---|---|
| 2021-09-17 | 2.60% 10-Q · filed 2021-11-03 | |
| 2021-09-07 | 0.00% 10-Q · filed 2022-11-03 | 2.60% 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |